Neuroleptic malignant syndrome and aripiprazole.
Hammerman
Seth
S
Department of Psychiatry, The Children's Hospital of Philadelphia.
Lam
Christopher
C
Department of Psychiatry, The Children's Hospital of Philadelphia.
Caroff
Stanley N
SN
Department of Psychiatry, University of Pennsylvania School of Medicine, Department of Veterans Affairs Medical Center, Philadelphia.
D000293:Adolescent; D014151:Anti-Anxiety Agents / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000068180:Aripiprazole; D003866:Depressive Disorder / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008607:Intellectual Disability / Q000188:drug therapy*; D008140:Lorazepam / Q000627:therapeutic use; D009459:Neuroleptic Malignant Syndrome / Q000188:drug therapy* / Q000209:etiology; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use*; D015363:Quinolones / Q000009:adverse effects / Q000627:therapeutic use*; D014481:United States
D014151:Anti-Anxiety Agents; D014150:Antipsychotic Agents; D010879:Piperazines; D015363:Quinolones; D000068180:Aripiprazole; D008140:Lorazepam